Orthofix Medical : OFIX March 2024 Investor Deck

Corporate Investor Deck

March 2024

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," or "continue" or other comparable terminology. Forward-looking statements in this communication include the Company's expectations regarding net sales and adjusted EBITDA for the year ended December 31, 2024. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to recruit and retain management and key personnel,

1. global economic instability and potential supply chain disruption caused by Russia's invasion of Ukraine and resulting sanctions, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.

This list of risks, uncertainties, and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law.

The Company is unable to provide expectations of GAAP income (loss) before income taxes, the closest comparable GAAP measures to Adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict without unreasonable efforts the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating Adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company's results computed in accordance with GAAP.

©2024 Orthofix Medical Inc. All rights reserved | 2

a

Extensive Portfolio	Improved Clinical	Large Addressable
Solutions with	Outcomes &	Markets with High
Complementary	Economic Value	Growth Opportunities
Technologies

Expanded Distribution		$150M Credit Facility		Visionary Leadership
Channels & Global		Provides Liquidity to		Team with Deep
Commercial Reach		Fund Growth and Scale		Sector Experience

Investment

Highlights

Building a Leading

Global Spine & Orthopedics

Company

©2024 Orthofix Medical Inc. All rights reserved | 3

Senior Leadership Team

Experienced leadership with 250+ years in spine/orthopedics

Massimo Calafiore		Julie Andrews		Suzanne Armstrong		Roberto Donadello		Kim Elting		Ehab Esmail
President and		Chief Financial Officer		Chief Human Resources Officer		Senior Vice President		President, Global Orthopedics and		Senior Vice President, Global Quality,
Chief Executive Officer						Global Operations		Interim Chief Legal Officer		Regulatory and Clinical Affairs

Tyler Lipschultz		Jill Mason		Jason Shallenberger		Beau Standish, PhD, PEng		Lucas Vitale		Frank Vizesi, PhD
President		VP , Corporate Counsel & Interim		President, Bone Growth Therapies		President		Chief People and Business		Chief Scientific Officer
Global Biologics		Chief Ethics & Compliance Officer				Global Enabling Technologies		Operations Officer

©2023 Orthofix Medical Inc. All rights reserved | 4

Complementary High Growth Portfolio

$7B of Focused High-Growth Market Segments* | 6.1% CAGR

Spinal Implants	Orthopedics

Motion Preservation

Spinal Fixation

Synergistic

Product

Platform

Limb Reconstruction Deformity Correction

Biologics		Bone Growth Therapies
Cellular Allograft		Bone Growth Stimulation
Demineralized Bone Matrices		Non-Surgical Alternative
Synthetic Bone Grafts		Regenerative Technology
		Enabling Technologies
		Machine-vision 7D FLASH	Navigation

SmartTRAK® 2022 - 2026 U.S. Estimates

*Focused growth segments include Enabling Technologies, Motion Preservation, Interbody, DBM, LLIF/OLIF, MIS and Long Bone Stimulation

©2024 Orthofix Medical Inc. All rights reserved | 5

Orthopedics

Specialized portfolio of limb reconstruction and deformity correction products

that address the most challenging orthopedic conditions

Complex Foot & Ankle		Complex Fracture		Adult & Pediatric Limb		Digital Healthcare
Reconstruction		Management		Reconstruction

TrueLok	AHN	TrueLok EVO	XCaliber	Fitbone®	TL-HEX
Ring Fixation	Ankle Hindfoot	Ring Fixation	Hybrid Fixator	Limb-Lengthening	TrueLok Hexapod
System	Nailing System	System		System	System

OrthoNext

Platform System for

Preoperative Planning

G-Beam	Galaxy	JuniOrtho
Fusion Beaming System	Fixation System	Pediatric Plating System

©2024 Orthofix Medical Inc. All rights reserved | 6

Spinal Implants

Comprehensive best-in-class spinal portfolio driving rapid market adoption

Cervical

M6-C	NorthStar®
Artificial Cervical Disc	Posterior Cervical
	Fixation System

Construx Mini	Shoreline®
PTC Spacer System	Anterior Cervical
with Nanovate	Standalone System
Technology

WaveForm C

Admiral

Thoracolumbar Fixation

Mariner®

Modular Pedicle Screw System

Firebird NXG

Spinal Fixation System

Mariner® Deformity

FIREBIRD SI

Interbodies

WaveForm	Forza TI
3D Interbody	Ti Spacer System
	with Nanovate
	Technology

Reef® TO		Meridian
NanoMetalene®
®	Spacer System
with Reef Topography

Explorer® TO

ForzaXP

3D Interbody	Anterior Cervical
Plating System

Adult Deformity Posterior	SI Fusion System	Expandable	Expandable Spacer
Fixation System		Interbody	System

©2024 Orthofix Medical Inc. All rights reserved | 7

Biologics

Full spectrum of biologic solutions

to enhance the fusion process and promote bone repair and growth

Cellular Allograft		Procedural Solutions		Demineralized Bone Fiber		Demineralized Bone Putty

Trinity Elite

OsteoBallast® OsteoBallast	NorthStar	OsteoStrand®	FiberFuse
MT	Facet Fusion

Plus

Torrent® & Torrent C

Accell Evo3® & Evo3® c

DynaGraft® II & OrthoBlast® II

Legacy

Synthetic		Graft Delivery		Traditional Allograft

Opus BA

Opus Mg Set

RAPID® O-Genesis

MozaikOsteoCove

©2024 Orthofix Medical Inc. All rights reserved | 8

Bone Growth Therapies

Safe and effective treatment and non-surgical alternative

to overcome bone healing challenges

				1,100,000
# 1 Prescribed bone growth	We are proud to be the	PEMF technology approved	Prescribed devices
first to offer a free
stimulator	recycling program so		Since 1986
	patients can properly
	dispose of their devices
	after use.
Bone Healing Therapy			Spine Fusion Therapy

PhysioStim	AccelStim		CervicalStim	SpinalStim
Bone Growth Therapy	Bone Healing Therapy		Spinal Fusion Therapy	Spinal Fusion Therapy

©2024 Orthofix Medical Inc. All rights reserved | 9

FLASHNavigation with 7D Technology

Machine-vision

Navigation System

Enabling

Technologies

Servicing the

full continuum

of surgical care

©2024 Orthofix Medical Inc. All rights reserved | 10